Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.41 |
| ▸ | LPL | P06858 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28352475 | 0.88 | CA1 (0.44) | TSHRLIPGLPLCA1CA2 | |
| SCHEMBL29951913 | 0.86 | LIPG (0.46) | TSHRLIPGLPLCA1CA2 | |
| SCHEMBL12098018 | 0.85 | LIPG (0.47) | TSHRLIPGLPLALDH1A1HSD17B10 | |
| SCHEMBL6963519 | 0.83 | TSHR (0.46) | TSHRLIPGLPLMEN1ALDH1A1 | |
| SCHEMBL552158 | 0.79 | TSHR (0.39) | TSHRCA2CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL22311215 | 0.77 | LPL (0.35) | TSHRLIPGLPLHSD17B10CYP1A2 | |
| SCHEMBL177379 | 0.76 | TSHR (0.48) | TSHRMEN1ALDH1A1KMT2AMGLL | |
| SCHEMBL29953913 | 0.76 | TSHR (0.48) | TSHRCYP2E1CYP3A4CYP2D6CYP2A6 | |
| SCHEMBL1944426 | 0.73 | TSHR (0.42) | TSHRMEN1ALDH1A1KMT2ACYP2D6 | |
| SCHEMBL31618300 | 0.73 | ALDH1A1 (0.42) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279627-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20230049452-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4090727-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | Danisco US Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021146255-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-3842531-A1 | COMPOSITIONS AND METHOD COMPRISING A LIPOLYTIC ENZYME VARIANT | Danisco US Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3833731-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | Danisco US Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10920204-B2 | Compositions and methods comprising a lipolytic enzyme variant | DANISCO US INC (US) | 2021-02-16 | — | — | US | disclosed |
| EP-2906691-B1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | DANISCO US INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10865398-B2 | Compositions and methods comprising a lipolytic enzyme variant | DANISCO US INC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20150291944-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | DANISCO US INC. (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2906691-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | Danisco US Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8871952-B2 | Thiophene compounds for liquid-crystalline media | MERCK PATENT GMBH (DE) | 2014-10-28 | — | — | US | disclosed |
| EP-2751263-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | Danisco US Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140187468-A1 | Compositions and Methods Comprising a Lipolytic Enzyme Variant | DANISCO US INC. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2014100018-A1 | NOVEL MANNANASE, COMPOSITIONS AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| CN-103646191-A | Virtual screening method for micromolecular reversible inhibitor of alkaline metalloproteinase from flavobacterium YS-80-122 | YELLOW SEA FISHERIES RES INST CHINESE ACAD FISHERY SCIENCES | 2014-03-19 | — | — | CN | disclosed |
| US-20140070141-A1 | THIOPHENE COMPOUNDS FOR LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2013033318-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | DANISCO US INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20110301360-A1 | THIOPHENE COMPOUNDS FOR LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301360-A1 | THIOPHENE COMPOUNDS FOR LIQUID-CRYSTALLINE MEDIA | CCNE2, CCNE1, C5 | TSHR 881/4885LIPG 2827/4885LPL 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.